Voloridge Investment Management LLC Trims Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Voloridge Investment Management LLC cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 91.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,776 shares of the biopharmaceutical company's stock after selling 177,471 shares during the period. Voloridge Investment Management LLC's holdings in Alnylam Pharmaceuticals were worth $3,948,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $33,000. OFI Invest Asset Management acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth about $35,000. Finally, IFP Advisors Inc increased its position in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 4.0%

NASDAQ ALNY traded up $11.69 during mid-day trading on Friday, reaching $304.59. The stock had a trading volume of 3,116,157 shares, compared to its average volume of 928,628. The stock has a market cap of $39.71 billion, a PE ratio of -140.36 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company has a fifty day moving average price of $259.91 and a 200 day moving average price of $254.83. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $305.82.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The company's revenue was up 20.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.16) EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on ALNY shares. UBS Group increased their price objective on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Needham & Company LLC reissued a "buy" rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 9th. Finally, Royal Bank of Canada increased their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the company's stock. According to MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $319.17.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.